Cephalon Inc. has agreed to pay $425 million to end a federal investigation into its marketing practices concerning sleep and pain drugs. It will also have to plead guilty to a misdemeanor charge of violating federal prescription drug laws. Cephalon was sued by the Pennsylvania Turnpike Commission for attempting to delay generic drug competition.
For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.
Admitted to practice law in all federal multidistrict litigation courts, the California State Bar and the Florida Bar. His philosophy is to provide aggressive, quality representations and seek fair compensation for individuals and their families who have suffered injury, death, or sexual abuse.
Comments for this article are closed.